Clinical effect of edaravone and dexborneol combined with Shuxuening in the treatment of acute cerebral infarction and its influence on serum Hcy and CRP
Objective To study the effect of edaravone and dexborneol combined with Shuxuening in the treatment of acute cerebral infarction(ACI)and its influence on serum homocysteine(Hcy)and C-reactive protein(CRP).Methods A total of 70 patients with ACI were randomly divided into a basic group and a scientific group by random sampling method,with 35 cases in each group.The basic group was treated with Shuxuening,and the scientific group was treated with edaravone and dexborneol in combination with Shuxuening.Comparison was made on coagulation function indexes[activated partial thromboplastin time(APTT),prothrombin time(PT),fibrinogen(FIB)],serum indexes(Hcy,CRP)and the score of National Institutes of Health Stroke Scale(NIHSS)before and after treatment,and the clinical efficacy.Results After medication,APTT and PT in both groups were longer than that before medication in this group,and FIB was lower than that before medication in this group;APTT of(37.07±8.12)s and PT of(15.16±3.12)s in the scientific group were longer than those of(29.15±6.23)and(12.45±2.14)s in the basic group;FIB of(3.28±0.32)g/L in the scientific group was lower than that of(4.17±0.23)g/L in the basic group;the differences were statistically significant(P<0.05).After treatment,Hcy and CRP in both groups were lower than those before treatment in this group;Hcy of(12.04±1.23)μmol/L and CRP of(0.61±0.25)mg/dl in the scientific group were lower than those of(15.36±1.42)μmol/L and(0.84±0.57)mg/dl in the basic group;the differences were statistically significant(P<0.05).After medication,NIHSS score in the two groups was lower than that before medication in this group,and the NIHSS score of(9.21±3.62)points in the scientific group was lower than that of(13.45±4.17)points in the basic group.The differences were statistically significant(P<0.05).The total effective rate of the scientific group was 97.14%,which was higher than that of 80.00%of the basic group,the difference was statistically significant(P<0.05).Conclusion Edaravone and dexborneol combined with Shuxuening in the treatment of ACI can reduce the neurological defect and improve the coagulation function,and improve the clinical efficacy,which is worth recommending.
Edaravone and dexborneolShuxueningAcute cerebral infarctionClinical effect
NETL
NSTL
万方数据
维普
